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MaBACKGROUND Remote monitoring (RM) of implantable cardioverter-deﬁbrillators (ICD) is an established technology
integrated into clinical practice. One recent randomized controlled trial (RCT) and several large device database studies
have demonstrated a powerful survival advantage for ICD patients undergoing RM compared with those receiving con-
ventional in-ofﬁce (IO) follow-up.
OBJECTIVES This study sought to conduct a systematic published data review and meta-analysis of RCTs comparing
RM with IO follow-up.
METHODS Electronic databases and reference lists were searched for RCTs reporting clinical outcomes in ICD patients
who did or did not undergo RM. Data were extracted from 9 RCTs, including 6,469 patients, 3,496 of whom were
randomized to RM and 2,973 to IO follow-up.
RESULTS In the RCT setting, RM demonstrated clinical outcomes comparable with ofﬁce follow-up in terms of all-cause
mortality (odds ratio [OR]: 0.83; p ¼ 0.285), cardiovascular mortality (OR: 0.66; p ¼ 0.103), and hospitalization (OR:
0.83; p ¼ 0.196). However, a reduction in all-cause mortality was noted in the 3 trials using home monitoring (OR: 0.65;
p ¼ 0.021) with daily veriﬁcation of transmission. Although the odds of receiving any ICD shock were similar in RM and IO
patients (OR: 1.05; p ¼ 0.86), the odds of inappropriate shock were reduced in RM patients (OR: 0.55; p ¼ 0.002).
CONCLUSIONS Meta-analysis of RCTs demonstrates that RM and IO follow-up showed comparable overall outcomes
related to patient safety and survival, with a potential survival beneﬁt in RCTs using daily transmission veriﬁcation.
RM beneﬁts include more rapid clinical event detection and a reduction in inappropriate shocks. (J Am Coll Cardiol
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ABBR EV I A T I ON S
AND ACRONYMS
CI = conﬁdence interval
CRT = cardiac
resynchronization therapy
CV = cardiovascular
HR = hazard ratio
ICD = implantable
cardioverter-deﬁbrillator
IO = in-ofﬁce
OR = odds ratio
RCT = randomized
controlled trial
RM = remote monitoring
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2592Remote monitoring (RM) of ICD devices
has been proposed as an alternative stra-
tegy to reduce the need for routine device
follow-up visits while providing continuous
surveillance and immediate problem notiﬁ-
cation (5). With this technology, ICDs can be
interrogated automatically using wireless
data transfer to the remote monitor. Patient
diagnostic information is then transmitted to
a central server that may be accessed by
treating clinicians through an Internet-based
interface or provide automatically generated
clinician alerts (6).SEE PAGE 2611Recently, clinical data presented in the IN-TIME
(Inﬂuence of Home Monitoring on Mortality and
Morbidity in Heart Failure Patients with Impaired
Left Ventricular Function) trial suggested that RM
could potentially lead to a decisive survival advan-
tage in ICD patients (7). This powerful survival beneﬁt
is supported by data from large-scale national device
registries, showing that RM may lead to a signiﬁcant
survival advantage over patients not using RM (8–10).
The ALTITUDE study, for example, followed a non-
randomized cohort of 69,556 patients implanted with
ICD or cardiac resynchronization therapy (CRT) de-
vices with deﬁbrillator capability (CRT-D) (Boston
Scientiﬁc Corporation, Natick, Massachusetts), and
identiﬁed a striking 50% reduction in mortality (ICD
hazard ratio [HR]: 0.56; CRT-D HR: 0.45; p < 0.0001)
in remote networked patients, compared with non-
networked device recipients (10). Similar mortality
reductions with RM use have been seen in 2 other
national device databases collectively enrolling more
than 100,000 ICD patients (8,9).
Until recently, there has been insufﬁcient ran-
domized controlled trial (RCT) evidence to evaluate
the overall impact of RM on clinical outcomes in ICD
patients. In the current study, we conducted a sys-
tematic review and meta-analysis of RCTs comparing
clinical outcomes in ICD patients undergoing RM
with those receiving conventional IO follow-up. We
speciﬁcally sought to evaluate the impact of RM on
all-cause and cardiovascular (CV) mortality, hospi-
talization, unscheduled clinic visits, atrial arrhythmia
detection, device shocks, and the time taken to clin-
ical decision or clinical event detection.
METHODS
We conducted a systematic search of PubMed,
Embase, Scopus, Web of Science, and the Cochrane
databases to identify RCTs comparing RM withconventional IO follow-up in ICD patients. The search
was conducted with the assistance of a research
librarian, and the details of the search grid are out-
lined in the Online Appendix. Databases were last
accessed on July 30, 2014 and results were updated
after the publication of the IN-TIME trial on August
16, 2014.
Two authors (A.N.G., N.P.) reviewed titles and
abstracts retrieved from our search strategy and
selected RCTs reporting on clinical outcomes of home
monitoring (treatment) of ICDs compared with con-
ventional IO follow-up (control). RCTs were included
if results were published in peer-reviewed journal
articles or as published abstracts with extractable
data. Studies were excluded if they provided
outcome data only from nonrandomized cohorts or
case series, evaluated ICDs but not RM, or evaluated
RM in contexts other than ICD patients. Figure 1
shows the number and reasons for exclusion of
publications extracted from the search strategy. For
included trials, all-cause mortality, hospitalizations,
unscheduled visits, shock delivery, and atrial ﬁbril-
lation detections were extracted by 2 authors (N.P.,
A.N.G.). Study quality was assessed on the basis of
adherence to the Consolidated Standards of Report-
ing Trials (CONSORT) statement.
STATISTICAL ANALYSIS. Statistical analysis was
performed with Comprehensive Meta-Analysis,
version 2 (Biostat, Inc., Englewood, New Jersey).
Odds ratios (OR) were used for dichotomous vari-
ables. The I2 statistic was used as a measure of vari-
ability in observed effect estimates attributable to
between-study heterogeneity (11). For variables
exhibiting mild heterogeneity (I2 #25%), pooled es-
timates were derived with ﬁxed-effects models. For
variables exhibiting more than moderate heteroge-
neity (I2 >25%), pooled estimates were derived with
random-effects models, according to the method of
DerSimonian and Laird (12). For time to detection of
clinical event/clinical decision data, variances were
imputed from interquartile ranges and 95% conﬁ-
dence intervals (CIs) according to the method of
Deeks et al. (13).
RESULTS
A total of 4,376 citations were retrieved after ex-
clusion of duplicates, then 3,491 citations were
excluded after initial screening of abstracts and
titles on general criteria, as related to topics other
than home monitoring of ICDs (Figure 1). Of 885
citations selected for a secondary review, we identi-
ﬁed 20 journal articles referencing 8 published
RCTs. An additional completed RCT, the EVATEL
FIGURE 1 RCT Search Flow Diagram
Search Databases: PubMed, Embase, Scopus, Cochrane, 
Web of Science
Search Date: August, 2014
Based on screening of abstracts
and titles on general criteria,
3,491 references were excluded.
Excluded references:
1) Related to ICD but not home
monitoring (n = 872)
2) Not pertinent to device therapy
(n = 2,501)
3) Preclinical studies (n = 118)
After detailed review of full-text
and/or abstract, 864 articles
were excluded.
Excluded references:
1) Observational cohort studies,
retrospective studies, and
surveys (n = 364)
2) Individual case reports
(n = 341)
3) Review articles (n = 158)
4) RCT not related to defined
outcomes (n = 1)
Include:
1) RCTs evaluated clinical
outcomes of RM versus IO (n = 8)
2) Sub-studies were grouped
under the main RCTs (n = 12)
3) 1 RCTs retrieved from relevant
abstract (n = 1)
4,376 references
885 references
21 references
9 RCTs
From a total of 4,382 citations, 9 randomized controlled trials (RCT) were selected to
compare remote monitoring (RM) with in-ofﬁce (IO) follow-up in implantable cardioverter-
deﬁbrillator (ICD) patients.
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a peer-reviewed published abstract with extractable
data (14).
BASELINE CHARACTERISTICS OF RCTS. A total of
6,469 patients were included in the 9 RCTs, all
published in the years 2010 through 2014 (Tables 1
and 2) (7,14–21). The sample size for each study var-
ied, from small (Perl et al. [19], n ¼ 36) to much larger
studies (Crossley et al. [17], n ¼ 1,997). Except for the
studies of Al-Khatib et al. (15) and Perl et al. (19),
most RCTs (78%) had been conducted at multiple
centers. The mean or median duration of follow-up
varied from 12 to 26 months. Inclusion criteria for
the studies are listed in Table 1. The mean age of
patients in the trials varied from 59 to 68 years. The
proportion of male patients in the studies ranged
from 43% to 88%. The mean left ventricular ejection
fraction varied from 26% to 35% and the mean pro-
portion of patients with underlying ischemic cardio-
myopathy ranged from 46% to 69%. Study quality
overall was strong based on adherence to the re-
porting principles of the CONSORT statement (Online
Appendix).
ALL-CAUSE AND CV MORTALITY. All-cause mortality
was reported in 7 trials enrolling 4,932 patients
(7,15–18,20,21). The OR for mortality with RM was not
statistically signiﬁcant from IO follow-up (OR: 0.83;
95% CI: 0.58 to 1.17; p ¼ 0.285; I2 ¼ 34.8%) (Figure 2).
CV mortality was reported in 4 trials (Central
Illustration). The OR for CV death showed a nonsig-
niﬁcant trend toward a reduction in CV mortality
with RM (OR: 0.66; 95% CI: 0.41 to 1.09; p ¼ 0.103;
I2 ¼ 35.1%).
To examine the stability of these ﬁndings, a series
of sensitivity analyses was undertaken. The only trial
to show a statistically signiﬁcant reduction in mor-
tality was IN-TIME (OR: 0.35; 95% CI: 0.17 to 0.73;
p ¼ 0.005) (7). Exclusion of IN-TIME eliminated the
trend toward improvement in all-cause mortality
(OR: 0.96; 95% CI: 0.74 to 1.24; p ¼ 0.737), and elim-
inated between-study heterogeneity (I2 ¼ 0.0%).
Exclusion of IN-TIME also reduced the trend toward
decreased CV mortality with RM (OR: 0.92; 95% CI:
0.50 to 1.70; p ¼ 0.800) and eliminated between-
study heterogeneity (I2 ¼ 0.0%). To examine the ef-
fect of trial size, we compared all-cause mortality in
the 3 trials with >500 patients with 4 trials with <500
patients. No difference in all-cause mortality was
identiﬁed between trials with >500 patients and trials
with <500 patients (p ¼ 0.939).
We also examined the effect of competing tech-
nologies. The 3 trials using home monitoring fromBiotronik SE & Co. KG (Berlin, Germany), which
incorporated daily veriﬁcation of home monitoring
transmission, showed a reduction in mortality with
RM (OR: 0.65; 95% CI: 0.45 to 0.94; p ¼ 0.021)
(7,16,21), but the 4 trials using CareLink (Medtronic,
Inc., Tempe, Arizona) did not (OR: 1.07; 95% CI: 0.77
to 1.49; p ¼ 0.767) (15,17,18,20).
IMPACT OF RM. Hospitalization data were reported
as an endpoint in 7 studies enrolling 5,372 patients.
Pooled data from all 7 studies showed no signiﬁcant
reduction in the odds of hospitalization with RM
TABLE 1 Enrollment Criteria for Included RCTs
Study (Ref. #) Number of Centers Eligibility Home Monitoring Group IO
Al-Khatib et al., 2010 (15) Single $18 yrs of age, have an ICD with or
without CRT for an approved indication,
devices followed-up at center, must
have a telephone (land line)
Patient-initiated transmissions every
3 months plus IO visit at 12 months
IO visit every 3 months
TRUST, 2010 (16) Multicenter $18 yrs of age, implanted within the last
45 days or being considered for implant
with a Biotronik ICD for class 1
indications, not pacemaker dependent
IO visit at 3 and 15 months;
RM replaced ofﬁce visits at
6, 9, and 12 months
IO visit every 3 months
CONNECT, 2011 (17) Multicenter $18 yrs of age, implanted with a Medtronic
Conexus-enabled CRT-D or ICD
IO visit at 1, 3, and 15 months;
RM replaced ofﬁce visits at
6, 9, and 12 months
IO visit every 3 months
EVOLVO, 2012 (18) Multicenter LVEF #35%, implanted with a wireless-
transmission-enabled Medtronic ICD
or CRT-D
IO visit at 8 and 16 months; RM
replaced ofﬁce visits at
4 and 12 months
IO visit every 4 months
EVATEL, 2012 (14) Multicenter $18 yrs of age, ﬁrst implantation of single-
or dual-chamber ICD in primary or
secondary prevention, ICD with
data-transmission features, GSM mobile
phone network at patient home
compatible with remote transmission
IO visit at 6 weeks and 12 months;
RM replaced ofﬁce visits at
3, 6, and 9 months
IO visit at 6 weeks,
then every 3 months
SAVE-HM, 2013 (19) Single ICD indicated for primary prevention of
sudden cardiac death in patients
experiencing chronic systolic heart
failure, geographically stable with a
stable medical condition, and sufﬁcient
GSM network coverage at their place of
residence
IO visit at 12 months; RM replaced
ofﬁce visits at 6 months
IO visit every 6 months
MORE-CARE, 2013 (20) Multicenter Left ventricular systolic dysfunction
(LVEF #35%), NYHA functional
class III to IV, QRS $120 ms, with
CRT-D devices
IO visit at 1 and 8 months; RM
replaced ofﬁce visits at
4 and 12 months
IO visit at 1 month,
then every 4 months
ECOST, 2013 (21) Multicenter Indication for single- or dual-chamber
ICD except for NYHA functional class IV
IO visit at 1–3 months and 15 and
27 months; RM replaced ofﬁce
visits at 9 and 21 months
IO visit at 1–3 months,
then every 6 months
IN-TIME, 2014 (7) Multicenter Indication ICD or CRT-D, heart failure
($3 months), NYHA functional class II or III,
LVEF #35%
IO visit at 12 months; RM replaced
ofﬁce visits at 6 months
IO visit every 6 months
All RM was activated automatically.
CONNECT ¼ Clinical Evaluation of Remote Notiﬁcation to Reduce Time to Clinical Decision; CRT ¼ cardiac resynchronization therapy; CRT-D ¼ cardiac resynchronization therapy-deﬁbrillator; ECOST ¼
Effectiveness and Cost of ICDs Follow-up Schedule with Telecardiology; EVATEL ¼ Evaluation of Tele Follow-up; EVOLVO ¼ Evolution of Management Strategies of Heart Failure Patients with Implantable
Deﬁbrillators; GSM ¼ global system for mobile communications; ICD ¼ implantable cardioverter-deﬁbrillator; IN-TIME ¼ Inﬂuence of Home Monitoring on Mortality and Morbidity in Heart Failure Patients
with Impaired Left Ventricular Function; IO ¼ in-ofﬁce; LVEF ¼ left ventricular ejection fraction; MORE-CARE ¼ Monitoring Resynchronization Devices and Cardiac Patients; NYHA ¼ New York Heart As-
sociation; RCT ¼ randomized clinical trial; RM ¼ remote monitoring; SAVE-HM ¼ Socio-economic Effects and Cost Saving Potential of Remote Patient Monitoring; TRUST ¼ Lumos-T Safely Reduces Routine
Ofﬁce Device Follow-up.
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(Figure 3A). The only trial reporting hospitaliza-
tion data to show a signiﬁcant reduction in hospital-
izations with RM was the TRUST (Lumos-T Safely
Reduces Routine Ofﬁce Device Follow-up) trial
(OR: 0.41; 95% CI: 0.30 to 0.56; p < 0.001) (16).
Exclusion of TRUST reduced the trend toward a
reduction in hospitalization (OR: 0.95: 95% CI: 0.84 to
1.08; p ¼ 0.442) and eliminated between-study het-
erogeneity (I2 ¼ 0.00%).
The impact of RM on unscheduled ofﬁce visit
burden was reported in 5 studies. Overall, RM
showed a nonsigniﬁcant trend toward an increase in
unscheduled visits (OR: 1.29; 95% CI: 0.99 to 1.67;
p ¼ 0.061; I2 ¼ 90.7%) (Figure 3B). Only 1 trial, EVOLO(Evolution of Management Strategies of Heart Fail-
ure Patients with Implantable Deﬁbrillators) (18),
showed a reduction in unscheduled visits with RM
(OR: 0.64; 95% CI: 0.48 to 0.86; p ¼ 0.003). Exclu-
sion of EVOLVO showed that RM use increased un-
scheduled ofﬁce visits (OR: 1.48; 95% CI: 1.16 to 1.89;
p ¼ 0.001).
The prevalence of patients receiving 1 or more ICD
shocks was reported in 4 studies. The odds of
receiving any ICD shock were similar in RM patients
to IO patients (OR: 1.05; 95% CI: 0.62 to 1.78;
p ¼ 0.861; I2 ¼ 52.5%) (Figure 4). However, 3 studies
including 2,085 patients reporting on inappropriate
shock recipients found a statistically signiﬁcant
reduction with RM when compared with IO follow-up
TABLE 2 Baseline Characteristics of Patients in Included RCTs
Study (Ref. #)
Sample
Size (n)
RM
(n)
IO
(n)
Average
Age (yrs)
Male
(%)
LVEF
(%)
Ischemic
Cardiomyopathy (%)
% CRT-D
Devices
Follow-Up
Duration (months)
Al-Khatib et al. (15) 151 76 75 63.0 72.5 — 58.5 18 12.0
TRUST (16) 1,339 908 431 63.7 42.5 28.75 67.0 0 12.0
CONNECT (17) 1,997 1,014 983 65.1 71.1 28.9 62.4 — 15.0
EVOLVO (18) 200 99 101 67.5 78.5 30.5 46.0 91 16.0
SAVE-HM (19) 36 18 18 62.7 86.1 — — 0 26.3
MORE-CARE (20) 148 76 72 67.5 73.6 27.0 48.0 100 12.0
ECOST (21) 433 221 212 61.6 88.2 34.9 65.4 0 24.2
EVATEL (14) 1,501 751 750 59.5 85.0 — 63.0 0 12.0
IN-TIME (7) 664 333 331 65.6 80.6 25.8 69.0 58 12.0
Abbreviations as in Table 1.
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(Central Illustration).
Atrial arrhythmia detection was assessed in 6 RCTs
enrolling 4,268 patients. There was no statistically
signiﬁcant change in the prevalence of atrial
arrhythmia detection between RM and IO follow-up
patients (OR: 1.24; 95% CI: 0.89 to 1.71; p ¼ 0.203;
I2 ¼ 39.8%) (Central Illustration).FIGURE 2 All-Cause Mortality
Study Name
Al-Khatib Study
TRUST
CONNECT
EVOLVO
MORE-CARE
ECOST
IN-TIME
0.01
Favors RM Favors IO
0.1 1 10 100
Odds Ratio and 95% Cl
All-cause mortality data were available for 7 RCTs, comprising
4,932 patients. The odds ratio for mortality with RM was
not statistically signiﬁcant from IO follow-up. Exclusion of the
IN-TIME trial reduced the trend toward reduced mortality
with RM and eliminated between-study heterogeneity. CI ¼
conﬁdence interval; CONNECT ¼ Clinical Evaluation of Remote
Notiﬁcation to Reduce Time to Clinical Decision; ECOST ¼
Effectiveness and Cost of ICDs Follow-up Schedule with
Telecardiology; EVOLVO ¼ Evolution of Management Strate-
gies of Heart Failure Patients with Implantable Deﬁbrillators;
IN-TIME ¼ Inﬂuence of Home Monitoring on Mortality and
Morbidity in Heart Failure Patients with Impaired Left Ven-
tricular Function; MORE-CARE ¼ Monitoring Resynchronization
Devices and Cardiac Patients; TRUST ¼ Lumos-T Safely
Reduces Routine Ofﬁce Device Follow-up; other abbreviations
as in Figure 1.An anticipated beneﬁt of RM is that it may facilitate
early detection of clinical events by ICD alerts, lead-
ing to the capacity to make early clinical decisions.
Time to clinical decision and/or event detection
was reported in 4 trials containing 3,176 patients
(16–18,20). A signiﬁcant decrease in the time to clin-
ical decision/event detection was noted in each of
these trials with RM compared with IO follow-up,
with a mean difference in days to clinical decision/
event detection of -27.1 days (95% CI: -40.1 to -13.3
days; p < 0.001) (Central Illustration).
A potentially important consideration in the effect
of RM is transmission rate and efﬁcacy. The RCTs in
the current study predominantly used 2 proprietary
technologies. The CareLink system (Medtronic, Inc.)
involves automated transmissions of pre-speciﬁed
clinician alerts for speciﬁc clinic events. The ear-
liest CareLink study (Al-Khatib et al. [15]) used a
version of RM requiring patient interaction that
was superseded and replaced with automated
transmission in the later studies. Three RCTs used
Biotronik RM technology. This technology also
generates automated pre-speciﬁed clinician alerts.
However, a speciﬁc feature with this technology is
that it involves daily transmission from the device to
the home monitor, with failure to transmit gener-
ating an alert to the clinician. Transmission efﬁcacy
and transmission delay data were presented in a
variety of formats, preventing meta-analysis of these
data. The results are presented in Table 3. Trans-
mission failure data were reported in 8 of 9 trials.
The lowest rates of failed transmission were seen in
the IN-TIME trial, with failure to transmit noted in 3
of 333 (0.9%) of RM patients. The study with the
highest rates of failed transmission was the
CONNECT (Clinical Evaluation of Remote Notiﬁca-
tion to Reduce Time to Clinical Decision) trial, in
which up to 45% of alerts in the RM group were not
transmitted.
CENTRAL ILLUSTRATION Effect of RM on Patient Safety and Survival
A B
C D
Parthiban, N. et al. J Am Coll Cardiol. 2015; 65(24):2591–600.
Remote monitoring (RM) has been proposed as an alternative to in-ofﬁce (IO) follow-up of implantable cardioverter-deﬁbrillators (ICD) to
reduce the need for ofﬁce visits while providing continuous surveillance and review of device data as well as immediate problem notiﬁcation. In
this meta-analysis of 9 randomized clinical trials comparing the 2 strategies, RM demonstrated a nonsigniﬁcant trend toward reduced car-
diovascular mortality (p ¼ 0.103) (A) and a signiﬁcant reduction in inappropriate shocks (p ¼ 0.002) (B). Although RM did not demonstrate
any signiﬁcant change in prevalence of atrial arrhythmia detection (C), it did signiﬁcantly decrease time to clinical decision/event detection
compared with IO follow-up, with a mean difference in days to clinical decision/event detection of –27.1 days (p < 0.001) (D). CI ¼ conﬁdence
interval; CONNECT ¼ Clinical Evaluation of Remote Notiﬁcation to Reduce Time to Clinical Decision; ECOST ¼ Effectiveness and Cost of ICDs
Follow-up Schedule with Telecardiology; EVATEL ¼ Evaluation of Tele Follow-up; EVOLVO ¼ Evolution of Management Strategies of Heart
Failure Patients with Implantable Deﬁbrillators; IN-TIME ¼ Inﬂuence of Home Monitoring on Mortality and Morbidity in Heart Failure Patients
with Impaired Left Ventricular Function; MORE-CARE ¼ Monitoring Resynchronization Devices and Cardiac Patients; TRUST ¼ Lumos-T Safely
Reduces Routine Ofﬁce Device Follow-up.
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RM has in recent years become an established tech-
nology that is increasingly integrated into the routine
clinical care of ICD patients. Several clinical studies
have demonstrated that ICD RM may offer a variety of
potential beneﬁts (Central Illustration) including
earlier notiﬁcation of clinical (17) and device (16)
events, reductions in hospital and resource use, and
improvements in follow-up adherence (9). On the
basis of these data, RM has been endorsed in current
guidelines and consensus documents as a safe alter-
native to IO follow-up of ICD patients (2–4).
Despite these potential advantages, RM is not
available to large numbers of patients around theworld. In North America, where RM is reimbursed (22),
it is estimated that RM is not used in as many as
50% of eligible patients (5). Signiﬁcant variation exists
in the uptake of RM between geographic regions and
health care systems (23). Possible reasons include
clinician reluctance to adopt RM because of lack of
familiarity with the technology, concerns about data
management and legal liability, and cost (5). RM
availability is even more constrained in many regions
outside North America, where reimbursement is
frequently unavailable to clinicians undertaking RM
(3,6,21).
IMPACT OF RM ON SURVIVAL. One possible reason
for the incomplete adoption of RM may be uncer-
tainty about whether RM has a signiﬁcant effect on
FIGURE 3 Hospitalization and RM Effect
on Unscheduled Visits
Study Name
A
B
Al-Khatib Study
TRUST
CONNECT
EVOLVO
SAVE-HM
MORE-CARE
TRUST
CONNECT
EVOLVO
MORE-CARE
ECOST
EVATEL
0.01
Fewer hospitalizations
with RM
Fewer unscheduled
visits with IO
More unscheduled
visits with RM
Fewer hospitalizations
with IO
0.1 1 10 100
0.01 0.1 1 10 100
Odds Ratio and 95% Cl
Study Name Point (raw) and 95% Cl
Hospitalization data were reported as endpoint in 7 studies,
comprising 5,372 patients. Pooled data from all 7 studies showed
no signiﬁcant reduction in the odds of hospitalization with RM
(A). The impact of RM on unscheduled ofﬁce visit burden was
reported in 5 studies, and overall, RM showed a nonsigniﬁcant
trend toward an increase in unscheduled visits (B). Abbreviations
as in Figures 1 and 2.
FIGURE 4 Effect of RM on ICD Shocks
Study Name
Al-Khatib Study
0.01
Fewer Shocks
with RM
Fewer Shocks
with IO
0.1 1 10 100
CONNECT
MORE-CARE
ECOST
Odds Ratio and 95% Cl
The incidence of patients receiving 1 or more ICD shock was re-
ported in 4 studies. The odds of receiving any ICD shock were
similar in RM and IO patients. Abbreviations as in Figures 1 and 2.
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2597patient clinical outcomes. An intriguing possibility,
raised by the recently published IN-TIME trial, is that
RM could drive a substantial improvement in survival
in ICD patients (7). In IN-TIME, RM led to an improved
heart failure composite score, a ﬁnding driven by a
sharp decrease in all-cause mortality in the RM group
(10 deaths in the RM arm vs. 27 deaths in the IO
follow-up arm) (7). Although a single speciﬁc mech-
anism responsible for the mortality beneﬁt was not
clear, the authors postulated that the improved out-
comes with RM may have occurred via a combination
of early ventricular and atrial arrhythmia detection,
early recognition of suboptimal biventricular pacing
on CRT-D devices, and increased telephone contact
with patients prompted by telemonitoring alerts (7).No statistical difference between RM and IO-follow-
up was identiﬁed for other heart failure measures
including heart failure hospital admission, New York
Heart Association functional class, and global self-
assessment (7).
The ﬁndings of IN-TIME have been supported by
nonrandomized data from large-scale device database
registries. The ALTITUDE study, which followed
69,556 patients, showed a statistically signiﬁcant 50%
reduction in mortality (ICD HR: 0.56; CRT-D HR: 0.45;
p < 0.001) in networked patients (10). The ﬁndings
presented in ALTITUDE were recently conﬁrmed by
PREDICT RM (Patient Related Determinants of ICD
Remote Monitoring Utilization and Outcomes), a
subgroup analysis in which 37,742 patients from the
ALTITUDE database were studied with matched
outcome data from the National Cardiovascular Data
Registry. In PREDICT RM, RM was associated with
reduced mortality (ICD HR: 0.60; CRT-D HR: 0.71)
(8,9). Similar data also have been presented for
148,976 patients on the Merlin patient care network
database (St. Jude Medical, Inc., Sylmar, California),
with RM use associated with increased survival (ICD
HR: 2.51; CRT-D HR: 2.44; both p < 0.001) (9). How-
ever, none of the analyses of the large RM databases
were randomized. The mortality of the group under-
going RM was compared with patients who chose not
to participate in RM or where the service was not
available. This may have potentially resulted in se-
lection bias and this should be considered when
interpreting outcomes of these studies.
In our study, we were unable to identify a signiﬁ-
cant overall all-cause mortality beneﬁt in meta-
analysis of the 7 RCTs reporting mortality data from
4,932 patients, with a nonsigniﬁcant reduction in the
odds of death with RM (OR: 0.83; 95% CI: 0.58 to 1.24;
TABLE 3 Summary of Transmission Efﬁcacy Data
Study (Ref. #) Failure of Transmission Delays to Transmission
Al-Khatib et al. (15) 6 patients (7.9%) failed to transmit
data at 3 months, 1 (1.3%)
patient failed to transmit
data at 6 months, and
2 (2.6%) patients failed
to transmit data at
9 months
TRUST (16) Daily RM transmissions were received
in 315,795 of a potential
363,450 days (87%)
22 of 2,275 (0.97%) scheduled
remote checks failed
CONNECT (17) 575 clinical events in RM arm; of
these events, 329 triggered an
automatic clinician alert; 246
clinical events did not trigger
automatic clinician alerts
because the alert was
programmed off (7%) or
the alert was not reset after
being previously triggered (93%)
180 automated clinician alerts (55%)
resulted in a successful
transmission to the CareLink
network; automatic clinician alerts
were triggered but not successfully
transmitted for 149 (45%) clinical
events, mainly because the home
monitor was not set up and
initiated to send out
transmissions
EVOLVO (18) In 57 events that occurred in 36
patients in the remote arm,
the time from the alert to
the transmission exceeded
3 days (e.g., patient not at
home, monitor accidentally
unplugged)
In 36 of these events,
transmission was
subsequently carried out
successfully; in the
remaining 21 cases, the
patient presented to the
hospital before data
transmission
SAVE-HM (19) 8% of 15 unscheduled follow-ups
Module B HM-ON regarded as
“failure of data transaction”
MORE-CARE (20) Of the 166 alerts in the RM group,
144 (87%) were successfully
transmitted; 22 alerts (13%) in
the RM group not successfully
transmitted because the patient
was admitted to hospital before
transmission (11 cases), the monitor
was not set up (8 cases), there
were connection problems with
the telephone line (2 cases),
and the patient was not at home
(1 case)
ECOST (21) Not reported Not reported
EVATEL (14) Telephone network not compatible
with remote transmission; 32 of
55 that switched from remote to
control (58.2%)
Patient unable to use the transmission
system correctly; 6 of 55 that
switched from remote to control
(10.9%)
Continued on the next page
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2598p ¼ 0.74). A nonsigniﬁcant trend toward a reduction in
the odds of CV death with RM was observed (OR: 0.69;
95% CI: 0.37 to 1.31; p ¼ 0.26), although this outcome
was reported in only 4 trials, so there may have been
insufﬁcient power to deﬁnitively assess this outcome.
However, a highly signiﬁcant mortality beneﬁt was
seen in the subset of trials using the Biotronik RM
system (OR: 0.65; 95% CI: 0.45 to 0.94; p ¼ 0.021)
(7,16,21). This beneﬁt was driven by the signiﬁcant
reduction in the rate of death in the IN-TIME trial in
RM patients (OR: 0.35; p ¼ 0.005). A possible mech-
anism to explain this advantage could include daily
veriﬁcation of RM transmission and/or the deﬁned
response mechanism to RM-generated alerts, and
represents an area to investigate in future trials.
Recent registry data have pointed to the possibility
that intensity of RM use may be a predictor of out-
comes (9). In the current study, transmission failure
and delays were identiﬁed in early trials using alter-
native technologies (Table 3), and may represent a
potential mechanism for the differences in survival
beneﬁt identiﬁed in our study.
IMPACT OF RM. An important potential clinical ad-
vantage of remote device monitoring identiﬁed in
observational studies is the potential for a reduction
in hospitalization. In PREDICT RM, RM was associated
with a signiﬁcant reduction in the rate of hospitali-
zation (HR: 0.81; 95% CI: 0.79 to 0.83) (8). In the cur-
rent study, a statistically signiﬁcant reduction in the
rate of hospitalization was not observed in the
included RCTs. Between-study heterogeneity was
driven by a single trial, TRUST; excluding this trial
reduced the trend toward a reduction in hospitaliza-
tion (OR: 0.95; 95% CI: 0.84 to 1.08; p ¼ 0.442) and
eliminated between-study heterogeneity (I2¼ 0.00%).
Again, the reasons for this difference between the
RCTs, and with previous observational registry data,
are not clear. Possible explanations include differ-
ences in patient selection in RCTs and potentially
more rigorous in-ofﬁce follow-up occurring in the RCT
context than in community-based follow-up.
A potential advantage for RM is its ability for
continuous surveillance to identify problems early,
thereby minimizing adverse outcomes including
shocks. In the included RCTs, RM was associated with
a similar level of shocks overall. Interestingly, how-
ever, a signiﬁcant reduction in inappropriate shocks
was recorded in the 3 RCTs providing information on
this outcome. Possible reasons for this could include
earlier detection of device/lead abnormalities or
timely detection and treatment of atrial arrhythmias.
An important aspect of RM technology is its ability
to detect abnormalities and clinical alerts early,
TABLE 3 Continued
Study (Ref. #) Failure of Transmission Delays to Transmission
IN-TIME (7) Of 333 participants allocated
to RM group, 3 had poor
transmission rate
Most frequent observation:
short gaps in data
transmission due to patients
who were absent from home
for 3 or more consecutive
days did not usually take
along the patient device that
relayed data to the central
monitoring unit and
investigation sites
Taking all telemonitored
patients together,
transmissions occurred on
85% of days per patient-
year
Abbreviations as in Table 1.
PERSPECTIVES
COMPETENCY IN PATIENT CARE AND PROCEDURAL
SKILLS: Meta-analysis of randomized trials suggests that
although RM may be associated with overall comparable levels
of survival among patients with implanted cardioverter-
deﬁbrillators, veriﬁcation of RM transmission data and appro-
priately coupled are potentially critical determinants of whether
clinical beneﬁt is maximized beneﬁt.
TRANSLATIONAL OUTLOOK: Further studies are needed to
clarify whether improved outcomes associated with RM tech-
nology derive from earlier detection of subclinical arrhythmias,
avoidance of inappropriate shocks, or speciﬁc therapeutic
interventions.
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2599presenting the possibility of expedited clinical inter-
vention. In our study, RM had a signiﬁcant advantage
in time to detection of clinical events or time to
clinical decision of –27.1 days (95% CI: –40.1 to
–13.3 days; p < 0.001). Early detection of events may
offer signiﬁcant beneﬁt in individual patients by
allowing tailored clinical intervention to prevent
clinical deterioration, such as early anticoagulation in
patients with atrial ﬁbrillation, or optimization of
device programming to maximize biventricular pac-
ing in patients with CRT-D devices.
CLINICAL IMPLICATIONS. In our study, we sought to
evaluate the clinical impact of RM in ICD patients in
RCTs, which represent the highest standard of clinical
evidence. At the present time, RM of ICDs is an
established technology, with broad, although not
universal, acceptance and availability among many
patients and clinicians worldwide. The results of our
study provide further evidence toward the safety re-
cord of RM. In our study, patients undergoing RM and
IO follow-up experienced comparable rates of all-
cause mortality, CV mortality, and hospitalizations.
At a minimum, our data provide convincing support
for the noninferiority of RM compared with IO follow-
up. An intriguing possibility of a substantial mortality
beneﬁt with RM has been seen in the IN-TIME trial,
suggesting that daily veriﬁcation of RM transmission
and a deﬁned response mechanism to RM-generated
alerts may be important in producing maximal
beneﬁt from the technology. These beneﬁts need
veriﬁcation in future studies. Additional advantages
seen with RM included statistically signiﬁcant re-
ductions in inappropriate shock and earlier detection
of clinical events. The relative equivalence in overall
clinical outcomes with guidelines-consistent ofﬁce-
based follow-up should provide reassurance to pa-
tients and clinicians in health systems and geographic
regions where RM is not available for logistical rea-
sons or cost.
STUDY LIMITATIONS. The study was conducted as a
systematic review and meta-analysis of RCTs with
available data reporting clinical outcomes with
RM in ICD patients in the RCT setting. A limitation of
this kind of study is that analyses are performed on
reported data in the published reports rather than
on primary study data. A further limitation of this
kind of study is the possibility of publication or
“ﬁle-drawer” bias, with the possibility that studies
favorable to the intervention are made available
for publication. Nevertheless, the results of our
study do summarize the outcomes of a number
of well-conducted randomized studies in >6,000
patients.CONCLUSIONS
RM of ICD patients is a technology that is now
established and part of routine clinical practice in
many centers worldwide. The results of RM RCTs
provide strong evidence of the safety of RM, with the
suggestion of a potential mortality beneﬁt with
technologies using daily transmission veriﬁcation.
Future investigations are needed to further explore
the key aspects of RM required to maximize the
clinical beneﬁt of this technology.
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